Condition: Dementia With Lewy Bodies · Sponsor: Helse Fonna
This is a confirmatory investigational medicinal product (IMP) study to investigate the effects on cognition, functional decline and on neuropsychiatric symptoms of the Glucocerebrosidase (GCase) enhancing chaperone ambroxol in participants diagnosed with prodromal and early dementia with Lewybodies (DLB).
This description comes directly from the study's public registry record.
Arvid Rongve, Phd · 90548749 · arvid.rongve@helse-fonna.no
Always discuss trial participation with your own doctor first.
| Helse Fonna | Haugesund, Haugesund, Norway | Recruiting |
| Haraldsplass Deaconess Hospital | Bergen, Norway | Recruiting |
| University Hospital, Akershus | Hågån, Norway | Recruiting |
| University Hospital, Akershus | Lørenskog, Norway | Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
| Stavanger University Hospital | Stavanger, Norway | Recruiting |
| University Hospital North-Norway | Tromsø, Norway | Recruiting |
| Trondheim University Hospital | Trondheim, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04588285